NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	Schizophrenia
Date of first enrollment	28/01/2011
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : LY2140023 INN of investigational material : Therapeutic category code : 117 Psychotropic agents Dosage and Administration for Investigational material : 20mg, 40mg or 80mg. Administered orally, twice daily for 104 weeks

Outcome(s)

Primary Outcome
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	Not applicable
Age maximum	Not applicable
Gender	Both
Include criteria	[Inclusion Criteria] -Must have met all entry criteria for, and have completed, an acute, placebo-controlled clinical trial of LY2140023 (such as Study H8Y-MC-HBBM, or other acute, placebo-controlled LY2140023 studies if allowed by the protocols for those studies). -Female patients of childbearing potential must agree to use a single, effective, medically acceptable method of birth control. -Patients must be considered reliable and have a level of understanding sufficient to perform all tests and examinations required by the protocol. -Patients must be able to understand the nature of the study and have given their own informed consent.
Exclude criteria